S&P 5007,691▲ 0.41%Nasdaq26,431▲ 1.11%Dow Jones51,966▼ 0.07%Nasdaq 10029,529▲ 1.17%VIX18.44▼ 7.75%US Dollar101.97▲ 0.13%Gold spot4,165▲ 0.21%WTI spot101.91▲ 1.04%
Home › DBV › Research report
← DBV page
XStocksXray
Market X-Ray report · 19 October 2026

DBV Technologies S.A. (DBV)

Euronext Paris · France · prices in EUR · close of 19 Oct 2026

Key indicators

Last closeEUR 1.594
52-week range1.534 – 4.500
Return, 1 month / 3 months−25.9% / −35.0%
Return, 1 year / 3 years−40.5% / −25.9%
TrendBelow its 200-day average
RSI (14)28
Volatility (1 year)63.8%
Worst drawdown (1 year)-63.2%
Average daily value traded2.38M EUR
Dividend yield–

Market X-Ray price-based

26/ 100 · High confidence · ahead of 15% of stocks on this exchange
Trend8
Momentum15
Stability (higher is calmer)21
Liquidity84
Income–

Five-year price chart navy: price · brown: 200-day average

0.211.613.014.415.812021-112023-022024-052025-072026-10

About the company

DBV Technologies is a clinical-stage biopharmaceutical company based in France that develops patch-based treatments for food allergies. Its main technology, Viaskin, delivers allergens through the skin to desensitise patients, and the company has focused on peanut allergy and milk allergy. Its customers are physicians and patients, chiefly children and their families, in allergy and paediatric care settings, and it works with regulators and clinical trial sites to advance its programmes.

The shares are listed on the Euronext Paris in France under the code DBV, and the price on this page is in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.

Summary

DBV Technologies S.A. (DBV) trades on the Euronext Paris in France. It last closed at EUR 1.594 on 19 October 2026.

Its price-based Market X-Ray is 26 out of 100 (a weak price profile), ranking 531 of 625 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.

Over the last year the price fell 40.5% and over the last three months it fell 35.0%. Returns are price returns, dividends not included.

Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.

stocksxray.com · page 1
XStocksXray
DBV Technologies S.A. (DBV)

The five lenses in numbers each metric is ranked against the other stocks on Euronext Paris

Lens and metricValueScoreReading
Trend8 · WeakBelow its long-term averages and far from its highs.
Above 200-day average-46.8%
From 52-week high-62.6%
Momentum15 · WeakLagging most stocks on this exchange.
3-month return-35.0%
6-month return-52.3%
12-month return, skipping the last month-19.8%
Stability (higher is calmer)21 · WeakVolatile, with deep drawdowns.
Volatility, 1 year (lower is calmer)63.8%
Worst drawdown, 1 year (smaller is calmer)-63.2%
Liquidity84 · StrongTrades actively.
Average daily value traded2.38M EUR
Zero-volume days0.0%
Income–Pays no dividend.
Dividend yield–
Years with dividends0

Strengths

  • Liquidity: Trades actively.

Weak spots

  • Trend: Below its long-term averages and far from its highs.
  • Momentum: Lagging most stocks on this exchange.
  • Stability (higher is calmer): Volatile, with deep drawdowns.

Returns

1 week−6.1%
1 month−25.9%
3 months−35.0%
6 months−52.3%
1 year−40.5%
3 years−25.9%
5 years−70.6%

Signals

50-day / 200-day average2.147 / 2.994
Golden / death cross (60 days)None
New 52-week highNo
Bullish RSI divergenceNo
Average daily range (ATR)0.094

Technical summary

DailyBearish4 bullish · 0 neutral · 12 bearish
WeeklyStrongly bearish1 bullish · 0 neutral · 11 bearish
MonthlyStrongly bearish1 bullish · 1 neutral · 6 bearish

How to read this report

Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Euronext Paris; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.

stocksxray.com · page 2 · generated 20 Oct 2026